Analysis of promoter non-CG methylation in prostate cancer

Matthew Truong, Bing Yang, Jennifer Wagner, Joshua Desotelle, David F. Jarrard

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. Materials & methods: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. Results: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. Conclusion: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
JournalEpigenomics
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Methylation
Prostatic Neoplasms
Neoplasms
Islands
Cell Line
Azacitidine
Cytosine
Methyltransferases
DNA Methylation
Embryonic Stem Cells
Genetic Promoter Regions
Vertebrates
DNA

Keywords

  • 5-azacytidine
  • epigenetics
  • EVX1
  • non-CG methylation
  • prostate cancer

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Truong, M., Yang, B., Wagner, J., Desotelle, J., & Jarrard, D. F. (2013). Analysis of promoter non-CG methylation in prostate cancer. Epigenomics, 5(1), 65-71. https://doi.org/10.2217/epi.12.67

Analysis of promoter non-CG methylation in prostate cancer. / Truong, Matthew; Yang, Bing; Wagner, Jennifer; Desotelle, Joshua; Jarrard, David F.

In: Epigenomics, Vol. 5, No. 1, 01.02.2013, p. 65-71.

Research output: Contribution to journalArticle

Truong, M, Yang, B, Wagner, J, Desotelle, J & Jarrard, DF 2013, 'Analysis of promoter non-CG methylation in prostate cancer', Epigenomics, vol. 5, no. 1, pp. 65-71. https://doi.org/10.2217/epi.12.67
Truong, Matthew ; Yang, Bing ; Wagner, Jennifer ; Desotelle, Joshua ; Jarrard, David F. / Analysis of promoter non-CG methylation in prostate cancer. In: Epigenomics. 2013 ; Vol. 5, No. 1. pp. 65-71.
@article{7e44e2358e5346008be7a7f426937f30,
title = "Analysis of promoter non-CG methylation in prostate cancer",
abstract = "Background: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. Materials & methods: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. Results: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. Conclusion: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.",
keywords = "5-azacytidine, epigenetics, EVX1, non-CG methylation, prostate cancer",
author = "Matthew Truong and Bing Yang and Jennifer Wagner and Joshua Desotelle and Jarrard, {David F.}",
year = "2013",
month = "2",
day = "1",
doi = "10.2217/epi.12.67",
language = "English (US)",
volume = "5",
pages = "65--71",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Analysis of promoter non-CG methylation in prostate cancer

AU - Truong, Matthew

AU - Yang, Bing

AU - Wagner, Jennifer

AU - Desotelle, Joshua

AU - Jarrard, David F.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. Materials & methods: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. Results: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. Conclusion: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.

AB - Background: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. Materials & methods: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. Results: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. Conclusion: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.

KW - 5-azacytidine

KW - epigenetics

KW - EVX1

KW - non-CG methylation

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84874025798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874025798&partnerID=8YFLogxK

U2 - 10.2217/epi.12.67

DO - 10.2217/epi.12.67

M3 - Article

C2 - 23414321

AN - SCOPUS:84874025798

VL - 5

SP - 65

EP - 71

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 1

ER -